多发性硬化中的神经退行性变和脱髓鞘。
Neurodegeneration and demyelination in multiple sclerosis.
机构信息
Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Division of Neuroimmunology, Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
出版信息
Neuron. 2024 Oct 9;112(19):3231-3251. doi: 10.1016/j.neuron.2024.05.025. Epub 2024 Jun 17.
Progressive multiple sclerosis (PMS) is an immune-initiated neurodegenerative condition that lacks effective therapies. Although peripheral immune infiltration is a hallmark of relapsing-remitting MS (RRMS), PMS is associated with chronic, tissue-restricted inflammation and disease-associated reactive glial states. The effector functions of disease-associated microglia, astrocytes, and oligodendrocyte lineage cells are beginning to be defined, and recent studies have made significant progress in uncovering their pathologic implications. In this review, we discuss the immune-glia interactions that underlie demyelination, failed remyelination, and neurodegeneration with a focus on PMS. We highlight the common and divergent immune mechanisms by which glial cells acquire disease-associated phenotypes. Finally, we discuss recent advances that have revealed promising novel therapeutic targets for the treatment of PMS and other neurodegenerative diseases.
进行性多发性硬化症(PMS)是一种免疫起始的神经退行性疾病,目前缺乏有效的治疗方法。尽管外周免疫浸润是复发缓解型多发性硬化症(RRMS)的标志,但 PMS 与慢性、组织受限的炎症和与疾病相关的反应性神经胶质状态有关。疾病相关小胶质细胞、星形胶质细胞和少突胶质细胞谱系细胞的效应功能开始被定义,最近的研究在揭示它们的病理意义方面取得了重大进展。在这篇综述中,我们讨论了导致脱髓鞘、失败性髓鞘再生和神经退行性变的免疫-神经胶质相互作用,重点是 PMS。我们强调了胶质细胞获得与疾病相关表型的常见和不同的免疫机制。最后,我们讨论了最近的进展,这些进展揭示了治疗 PMS 和其他神经退行性疾病的有前途的新治疗靶点。
相似文献
Neuron. 2024-10-9
Adv Neurobiol. 2024
Handb Clin Neurol. 2014
Acta Neuropathol Commun. 2017-3-24
Trends Immunol. 2024-10
Prostaglandins Leukot Essent Fatty Acids. 2011-5-6
引用本文的文献
Discov Immunol. 2025-4-29
Antioxidants (Basel). 2025-4-28
ACS Med Chem Lett. 2025-4-2
Adv Sci (Weinh). 2025-5
Glia. 2025-6
本文引用的文献
Cell Stem Cell. 2024-11-7
Neurol Neuroimmunol Neuroinflamm. 2024-3